Carmen M. Klass, MD, PhD

Northwest Georgia Oncology Centers, P.C. Marietta Cancer Center 340 Kennestone Hospital Blvd.
Suite 200
Marietta, GA 30060
Phone: (770) 281-5100
Fax: (678) 581-7100

Carmen M. Klass, MD, PhD moved to the United States in 1996 from her native Germany to become a Research Fellow in Cell Biology at the University of Alabama at Birmingham and complete her cancer training at the Winship Cancer Institute at Emory University in Atlanta where she received numerous honors for her clinical skills and research.

Upon completion of her Fellowship, Dr. Klass worked as a staff physician at the Atlanta VA Medical Center. In 2007, she joined the cancer care team of Northwest Georgia Oncology Centers, P.C. (NGOC) in Marietta.

Specializing in the treatment of breast and gastrointestinal cancers, Dr. Klass is actively involved in cancer research and clinical trials to find a cancer cure and provide her patients with the most advanced cancer treatment available in Georgia.

Dr. Klass provides patient-centered cancer care at NGOC’s Marietta Cancer Center.

Personal DataBirthplace: Tuttlingen, Western Germany
Undergraduate EducationBS Pre-Med, September 1989
Ruhr Universitaet, Bochum, Germany
Medical EducationDoctor of Medicine, 1994
Eberhard Karls Universitaet
Tuebingen, Germany

PhD, Clinical Chemistry, 1996
Eberhard Karls Universitaet
Tuebingen, Germany
Postdoctoral TrainingRESIDENCY
Internal Medicine
Georg August University Hospital
Goettingen, Germany
July 1994 – November 1996

PhD, Internal Medicine
Eberhard Karls Universitaet
Tuebingen, Germany
July 1991 – June 1996

Research Fellow, Cell Biology
University of Alabama
Birmingham, AL
November 1996 – July 2000

RESIDENCY
Internal Medicine
Emory University School of Medicine
Atlanta, GA
August 2000 – July 2003

FELLOWSHIP
Hematology and Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, GA
August 2003 – August 2006
Board CertificationAmerican Board of Internal Medicine, Internal Medicine 2003
American Board of Internal Medicine, Medical Oncology, 2006
American Board of Internal Medicine, Hematology, 2006
Medical LicensureState of Georgia, 2003 (Active)
Professional SocietiesAmerican Society of Clinical Oncology
American Association for Cancer Research
Georgia Society of Clinical Oncology
HonorsRecipient of Research Scholarship of the German Research Foundation, 1996 -1998
Recipient of “Best Resident’s Award," Ambulatory Medicine, 2000 - 2001
Recipient of “Best Resident’s Award." Medicine of the Faculty, 2002 - 2003
Recipient of “ECOG Young Investigator Award for Clinical Translational Science," 2004
Recipient of Clinical Scholar Award, Drug Development Academy, 2004 – 2006
Chief Fellow, Department of Hematology/ Oncology, Emory University School of Medicine, 2005 - 2006
Publications (not inclusive)Klass CM, Krug, L.T., Pozharskaya, V., and Offermann, M.K. (2005). The Targeting of Primary Effusion Lymphoma Cells for Apoptosis by Inducing Lytic Replication of Human Herpesvirus 8 While Blocking Virus Production. Blood, 105(10):4028-34.

Klass CM and Offermann M.K. (2005). Therapeutic strategies to target Human herpesvirus-8. Current Opinion in Oncology, 17(5):447-55.

Klass CM, Shin, D.M. and Khuri, F.R. (2005). New Directions in Chemoprevention of the Head and Neck Cancer Patient. ASCO 2005 Education Book, 454-460.

Klass CM, Choe MS, Chen Z, Zhang X, Shin DM (2007). Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor
receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clin Cancer Res. 13(10):3015-23.

Klass CM, McLean JN, Nunley SR, Moore C, Muller S, Johnstone PA. (2007). Combined modality therapy of esthesioneuroblastoma. Otolaryngol Head Neck Surg. 136(6):998-1002.

Klass CM, and Shin, D.M. (2007). Current status and future perspectives of chemoprevention in head and neck cancer. Current Cancer Drug Targets, 7(7):623-32.

Klass CM, Choe MS, Hurwitz SJ, Tighiouart M, Zhang X, Chen ZG, Shin DM. Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer. Head Neck, 10:1263-73.

Major Research InterestsClinical Trials (Oncology & Hematology)